Published November 14, 2018 | Version v1
Dataset Open

Finding an antibody to detect EZH1 protein expression – Part 4

Creators

  • 1. Structural Genomics Consortium, Princess Margaret Cancer Centre, University Health Network
  • 2. Structural Genomics Consortium, University of Toronto
  • 3. Princess Margaret Cancer Centre, University Health Network, University of Toronto
  • 4. Structural Genomics Consortium, Princess Margaret Cancer Centre, University Health Network, University of Toronto

Description

Follow up to previous posts where we determine that we have an antibody to detect EZH1 expression in AML patient cells.

Notes

The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome [106169/ZZ14/Z]. This project receives funding from the Leukemia and Lymphoma Society of Canada.

Files

11-14-18 EZH1 antibody optimization part 4.pdf

Files (308.4 kB)

Name Size Download all
md5:3d362c432ac92d571645628eaf7f52a0
69.6 kB Download
md5:190aa747e75eba91a047adff301ff728
238.8 kB Preview Download